- Home
- MDIA vs KLRS Comparison
MDIA vs KLRS Comparison
Compare MDIA & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDIA | KLRS |
|---|---|---|
| Founded | 2019 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.0M | 46.0M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | MDIA | KLRS |
|---|---|---|
| Price | $0.62 | $10.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $20.67 |
| AVG Volume (30 Days) | 38.7K | ★ 54.9K |
| Earning Date | 03-02-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $95,571,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 195.05 | N/A |
| 52 Week Low | $0.54 | $2.14 |
| 52 Week High | $1.60 | $11.90 |
Technical Indicators
Market Signals| Indicator | MDIA | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 45.11 | 55.24 |
| Support Level | $0.56 | $8.08 |
| Resistance Level | $0.65 | $10.36 |
| Average True Range (ATR) | 0.05 | 1.11 |
| MACD | 0.00 | 0.10 |
| Stochastic Oscillator | 51.50 | 71.61 |
Price Performance
Historical ComparisonAbout MDIA Mediaco Holding Inc.
MediaCo Holding Inc is a radio broadcasting media company operating in radio and digital advertising, premium programming, and events. It has two radio stations, WQHT-FM and WBLS-FM, which serve the New York City metropolitan area. The company generates revenue from radio and outdoor advertising sales, events including sponsorships and ticket sales, licensing, and syndication. The company has two business segments: the Audio segment and the Video segment. The company generates the majority of its revenue from the Audio segment.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.